Rife machine for cancer: Does it work, and are there any risks?

Rife machine for cancer: Does it work, and are there any risks?

Rife machine for cancer: Does it work, and are there any risks?

The Rife machine delivers a low energy electromagnetic frequency into the body. It usually consists of a controller box and two electrical pads that a person attaches to their hands or feet. Proponents claim that it can cure cancer and HIV, but there is no scientific evidence to support this. Learn more here..
The Rife machine delivers a low energy electromagnetic frequency into the body. It usually consists of a controller box and two electrical pads that a person attaches to their hands or feet. Proponents claim that it can cure cancer and HIV, but there is no scientific evidence to support this. Learn more here.

Rife machine for cancer: Does it work, and are there any risks?

Early-Stage Triple-Negative Breast Cancer Journey: Beginning, End

Rife machine for cancer: Does it work, and are there any risks?

Bone-Specific Enhancement of Antibody Therapy for Breast Cancer

Rife machine for cancer: Does it work, and are there any risks?

Results of a multicenter cluster-randomized controlled clinical

Rife machine for cancer: Does it work, and are there any risks?

Opinion How I Became Extremely Open-Minded - The New York Times

Rife machine for cancer: Does it work, and are there any risks?

Intelligent Nanoplatform Integrating Macrophage and Cancer Cell

Rife machine for cancer: Does it work, and are there any risks?

Magnet Therapy Memorial Sloan Kettering Cancer Center

Rife machine for cancer: Does it work, and are there any risks?

The CRISPR revolution: it's transforming cancer research, can it

Rife machine for cancer: Does it work, and are there any risks?

A blood test for early detection of any cancer: What's the ideal

Rife machine for cancer: Does it work, and are there any risks?

Rife Machine for Cancer: Does It Work? Claims, Research, and Risks

Rife machine for cancer: Does it work, and are there any risks?

Mitigating risk in academic preclinical drug discovery